HMNC Brain Health (HMNC) has completed the subject randomisation in its placebo-controlled Phase IIb OLIVE trial of a vasopressin V1b receptor antagonist, BH-200, for major depressive disorder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback